Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Incidence of Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the Intensive Care Unit: a Retrospective Analysis

ID
Name
Sevoflu-DI-IZ
Description
The investigators aim to retrospectively explore the electronic medical records of all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (\>24h) with sevoflurane.
Trial arms
Trial start
2021-05-26
Estimated PCD
2023-04-01
Trial end
2023-04-01
Status
Completed
Treatment
Sevoflurane
Sevoflurane administration to sedate the patient
Arms:
Sevoflurane group
Size
1000
Primary endpoint
Nephrogenic Diabetes Insipidus prevalence
up to 8 weeks
Eligibility criteria
Inclusion Criteria: * Sevoflurane administration \>24h * 18 years and older Exclusion Criteria: * \< 18 years old * Pre-existing diabetes insipidus * Use of drugs at risk for diabetes insipidus (including lithium, cisplatin) * Hypercalcemia (persistently \>2.75 mmol/L) * Pituitary or acute brain surgery * Patients requiring continuous renal replacement therapy * Pregnancy
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 1000, 'type': 'ACTUAL'}}
Updated at
2023-04-27

1 organization

1 product

1 indication

Organization
Universitair Ziekenhuis Brussel
Product
Sevoflurane
Indication
Nephrogenic Diabetes Insipidus